Pharmaceutical group spent $6.3M lobbying in Q4 The Associated Press PhRMA lobbied on multiple aspects of the health care overhaul, including several bills to allow approval of generic versions of expensive biologic drugs ... |
 RTT News | Obamacare? Who Cares? There Are Drug Deals To Do Wall Street Journal (blog) Then there is the showdown for German generic maker Ratiopharm Gmbh, which is that county's second-largest generic drug firm. Pfizer has wheeled out a bid ... Novartis to sell $5B in bonds for Alcon buy; Abbott to buy Facet Biotech; |
Abbott Labs spent nearly $2 million on lobbying The Associated Press The company also lobbied on a provision designed to give the Food and Drug Administration the authority to approve generic versions of biotech drugs. ... |
Abbott Laboratories spent $1.9 million in 4th quarter to lobby on health reform Los Angeles Times The company also lobbied on a provision designed to give the Food and Drug Administration the authority to approve generic versions of biotech drugs. ... |
 RTT News | Generic drugmaker Teva names Frost as chairman The Associated Press Teva sells some brand-name drugs and also challenges the patents of others to get approval to sell generic versions before the patents expire. ... Teva names Frost to replace generic drug hero Hurvitz Teva Announces the Appointment of Dr. Philip Frost as Chairman of Its Board of ... Teva appoints new chairman of board of directors |
Biotech looks healthy InvestmentNews Currently there is no regulatory approval process for generic versions of biotechnology drugs (biogenerics) whose patents have expired. ... |
Bristol-Myers sees no generic hit Investor's Business Daily It's trying to offset the anticipated revenue loss by acquiring biotech drugs or small biotech firms in a strategy to remake itself as a biopharmaceutical ... |
Japanese drug makers put up a fight MarketWatch (NYSE:MRK) plans to launch Japanese sales of a generic biotech drug to treat anemia in 2012 or later, the Nikkei business daily reported Wednesday. ... |
Pfizer catches hedge funds' interest Reuters Pfizer's experimental drugs include treatments for Alzheimer's disease, cancer, pain and diabetes. Six vaccines and 27 biotech drugs -- complex injectable ... |
White House tilts at barrier to cheap drugs Financial Times ... generic versions of biotech drugs to be brought to market earlier than the 12-year delay period proposed in both the Senate and House reform bills. ... |
